Search

Your search keyword '"Leung, Nelson"' showing total 3,095 results

Search Constraints

Start Over You searched for: Author "Leung, Nelson" Remove constraint Author: "Leung, Nelson"
3,095 results on '"Leung, Nelson"'

Search Results

1. Treatment patterns for AL amyloidosis after frontline daratumumab, bortezomib, cyclophosphamide, and dexamethasone treatment failures

2. Chimeric antigen receptor T-cell therapy associated hemophagocytic lymphohistiocytosis syndrome: clinical presentation, outcomes, and management

3. Diagnostic yield of exome and genome sequencing after non-diagnostic multi-gene panels in patients with single-system diseases

4. Outcomes of patients with multiple myeloma refractory to standard dose vs low dose lenalidomide

5. Assessment of Glomerular Filtration Rate in Patients with Cancer: A Statement from the American Society of Onco-Nephrology

6. Assessment of GFR in Patients with Cancer Part 2: Anticancer Therapies – Perspectives from the ASON

7. Correction: Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab

8. Correction: Family history of plasma cell disorders is associated with improved survival in MGUS, multiple myeloma, and systemic AL amyloidosis

10. Correction: Value of bone marrow examination in determining response to therapy in patients with multiple myeloma in the context of mass spectrometry-based M-protein assessment

12. Association of Thrombocytopenia With Disease Burden, High-Risk Cytogenetics, and Survival in Newly Diagnosed Multiple Myeloma Patients Treated With Novel Therapies

14. Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia. 2022 Jul;36(7):1720–1748

15. Multimode photon blockade

16. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms

19. Comparison of daratumumab-based regimens as second-line therapy in relapsed/refractory multiple myeloma

20. Long-term outcomes of allogeneic stem cell transplant in multiple myeloma

22. Defining drug/drug class refractoriness vs lines of therapy in relapsed/refractory multiple myeloma

24. Autosomal dominant ApoA4 mutations present as tubulointerstitial kidney disease with medullary amyloidosis

29. Multimode photon blockade

30. Impact of cytogenetic abnormalities on the risk of disease progression in solitary bone plasmacytomas

32. Value of bone marrow examination in determining response to therapy in patients with multiple myeloma in the context of mass spectrometry-based M-protein assessment

33. Outcomes of patients with primary refractory multiple myeloma in the era of triplet and quadruplet induction therapy

34. Partial Compilation of Variational Algorithms for Noisy Intermediate-Scale Quantum Machines

35. Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group

36. Optimized Compilation of Aggregated Instructions for Realistic Quantum Computers

37. Outcomes after biochemical or clinical progression in patients with multiple myeloma

39. Pathological characteristics of light chain crystalline podocytopathy

41. Complement gene variant effect on relapse of complement-mediated thrombotic microangiopathy after eculizumab cessation

42. First relapse in patients with multiple myeloma: Outcomes and predictors.

43. A Dissipatively Stabilized Mott Insulator of Photons

45. Phase 2 trial of ixazomib, cyclophosphamide, and dexamethasone for previously untreated light chain amyloidosis

49. Clinical activity of single-dose systemic oncolytic VSV virotherapy in patients with relapsed refractory T-cell lymphoma

50. Family history of plasma cell disorders is associated with improved survival in MGUS, multiple myeloma, and systemic AL amyloidosis

Catalog

Books, media, physical & digital resources